血清可溶性VSIG4作为淋巴瘤相关噬血细胞综合征诊断替代标志物
Lymphoma-associated haemophagocytic lymphohistiocytosis (L-HLH) is characterized by excessively activated macrophages and cytotoxic T lymphocytes, but few reliable markers for activated macrophages are available clinically.…
要点
- sVSIG4可能作为活化巨噬细胞的替代标志物用于L-HLH诊断。
核心结论
- sVSIG4可能作为活化巨噬细胞的替代标志物用于淋巴瘤患者L-HLH的诊断。
研究设计与样本
- 先用定量质谱筛选伴与不伴L-HLH的淋巴瘤患者血清差异蛋白,再用ELISA验证sVSIG4浓度。
主要发现
- 质谱筛选显示巨噬细胞特异性表达的sVSIG4在L-HLH组显著上调。
- ELISA证实伴L-HLH的淋巴瘤患者sVSIG4浓度显著升高。
临床怎么用
- 对淋巴瘤患者可检测血清sVSIG4辅助诊断L-HLH,cut-off 2195 pg/ml。
- sVSIG4>2195 pg/ml提示1年总生存极差,应加强病情评估。
局限性
- 研究设计为2016至2018年间的单次生物标志物发现与验证。
- sVSIG4作为替代标志物的结论尚需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphoma-associated haemophagocytic lymphohistiocytosis (L-HLH) is characterized by excessively activated macrophages and cytotoxic T lymphocytes, but few reliable markers for activated macrophages are available clinically. This study, designed to discover novel biomarkers for the diagnosis of lymphoma patients with L-HLH, was initiated between 2016 and 2018. Fifty-seven adult lymphoma patients were enrolled - 39 without HLH and 18 with HLH. The differential serum protein expression profile was first screened between lymphoma patients with and without L-HLH by a quantitative mass spectrometric approach. Soluble V-set and immunoglobulin domain-containing 4 (sVSIG4), specifically expressed by macrophages, was significantly upregulated in the L-HLH group. Subsequently, sVSIG4 concentration was confirmed by enzyme-linked immunosorbent assay to be significantly increased in lymphoma patients with L-HLH. When it was exploited for the diagnosis of lymphoma patients with L-HLH, the area under a receiver operating characteristic curve was 0·98 with an optimal cut-off point of 2195 pg/ml and the corresponding sensitivity and specificity were 94·44% and 94·87% respectively. In addition, the one-year overall survival was significantly worse in patients with a sVSIG4 concentration above 2195 pg/ml compared with those below 2195 pg/ml (5·3% vs. 72·2%, P < 0·0001). sVSIG4 may be a surrogate marker of activated macrophages for the diagnosis of lymphoma patients with L-HLH.
引用
- Yuan S, Wang Y, Luo H, et al. Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis. Br J Haematol. 2020. PMID: 31960419. doi:10.1111/bjh.16299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。